We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Monocyte Distribution Width Evaluated as a Sepsis Indicator

By LabMedica International staff writers
Posted on 01 Jul 2021
Print article
Image: The DxH 900 hematology analyzer enables the high-volume laboratory to achieve RBC, PLT and WBC differentials through near native-state cellular characterization (Photo courtesy of Beckman Coulter)
Image: The DxH 900 hematology analyzer enables the high-volume laboratory to achieve RBC, PLT and WBC differentials through near native-state cellular characterization (Photo courtesy of Beckman Coulter)
Most current automated hematology analyzers have enhanced cell counting functions including the addition of new cell types such as nucleated red blood cells or immature granulocytes, making it possible to obtain a precise quantification of peripheral blood cells in pathological conditions.

Cellular analysis technologies are able to explore qualitative aspects of leukocytes (white blood cells, WBCs) and provide numerous additional parameters, indicating functional information for each leukocyte type, the so-called cell population data (CPD). Since sepsis represents a life-threatening condition, without characteristic signs or symptoms, early detection for timely and appropriate management is crucial to patient survival.

Medical Laboratorians at the University-Hospital of Padova (Padova, Italy) evaluated the diagnostic accuracy and prognostication of monocyte distribution width (MDW) in sepsis for patients admitted to Intensive Care Units (ICU). The scientists conducted a prospective observational study during the hospitalization of 506 adult patients admitted to the ICU. MDW was evaluated in 2,367 consecutive samples received for routine complete blood counts (CBC) performed once a day and every day during the study. Sepsis was diagnosed according to Sepsis-3 criteria and patients enrolled were classified in the following groups: no sepsis, sepsis, and septic shock. There were 346 men and 160 women, aged from 18 to 89 years (median 68 years) in the study.

Complete blood count (CBC) and MDW were analyzed using the UniCel DxH 900 (Beckman Coulter, Inc, Brea, CA, USA). At the same time, 2,128 samples were determined for C-reactive protein (CRP) and 2,035 samples for procalcitonin (PCT), as part of the clinical examination. Serum CRP was determined using a nephelometric/turbidimetric technique of the Dimension Vista System (Siemens Healthcare GmbH, Milan, Italy). PCT was determined using chemiluminescence immunoassay (CLIA) technology with paramagnetic microparticle solid phase of the LIAISONs BRAHMS PCTs II GEN System (DiaSorin, Saluggia, Italy).

The investigators reported that MDW values were significantly higher in patients with sepsis or septic shock in comparison to those within the no sepsis group: median 26.23, 28.97, and 21.99 respectively. ROC analysis demonstrated that AUC is 0.785 with a sensitivity of 66.88% and specificity of 77.79% at a cut-off point of 24.63. In patients that developed an ICU-acquired sepsis MDW showed an increase from 21.33 to 29.19. MDW increase was not affected by the etiology of sepsis, even in patients with COVID-19. In sepsis survivors a decrease of MDW values were found from the first time to the end of their stay: median from 29.14 to 25.67.

The authors concluded that MDW, a parameter that reflects a change in circulating monocytes volume in response to pro-inflammatory signals from infectious organisms referred to as pathogen-associated molecular patterns, can have potential clinical applications for early sepsis detection in hospital and ICU settings. The study was published on the July, 2021 issue of the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
University-Hospital of Padova
Beckman Coulter
Siemens Healthcare
DiaSorin


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.